abacavir

(redirected from Triumeq)
Also found in: Dictionary.
Related to Triumeq: Abacavir, Stribild

abacavir

 [ah-bak´ah-vir]
a non-nucleoside reverse transcriptase inhibitor used as an antiretroviral in treatment of human immunodeficiency virus infection; administered orally as the sulfate salt.

abacavir

/abac·a·vir/ (ah-bak´ah-vir) a nonnucleoside reverse transcriptase inhibitor used as the sulfate salt as an antiretroviral in the treatment of human immunodeficiency virus infection.

abacavir

(ə-băk′ə-vîr′)
n.
An antiviral drug, C14H18N6O, that is a nucleoside reverse transcriptor inhibitor and is used in its sulfate form in combination with other drugs for the treatment of HIV infection.

abacavir

an antiviral that is a nucleoside reverse transcriptase inhibitor.
indication It is prescribed in combination with other antiretroviral agents for HIV-1 infection.
contraindication Known hypersensitivity to this drug prohibits its use.
adverse effects Hypersensitivity reactions occur in approximately 5% of patients, and can be fatal. Other life-threatening adverse effects include granulocytopenia, anemia, and lactic acidosis. Common side effects include fever, headache, malaise, insomnia, nausea, vomiting, diarrhea, anorexia, and rash.

abacavir

An HIV-nucleoside reverse-transcriptase inhibitor (NRTI/integrase inhibitor) similar to AZT.
 
Adverse effects
Life-threatening allergic reactions—fever, dyspnea, rashes, intraoral blistering, nausea, headache.

abacavir

Ziagen, zintavir, 1592 AIDS An HIV nucleoside reverse transcriptase inhibitor–NRTI/integrase inhibitor similar to AZT Adverse effects Life-threatening allergic reactions–fever, dyspnea, rashes, intraoral blistering, nausea, headache. See AIDS, Nucleoside reverse transcriptase inhibitor, Reverse transcriptase.

abacavir

A nucleoside reverse transcriptase inhibitor drug used in combination with other anti-HIV drugs to treat AIDS. A brand name is Ziagen. In combination with lamivudine and zidovodine it is marketed as Trizivir.
References in periodicals archive ?
ViiV Healthcare on Monday provided an update from the 48-week phase IIIb, open-label, international, multi-centre ARIA study of Triumeq (dolutegravir/abacavir/lamivudine) for the treatment-naive women living with HIV.
Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare): Nearly half of Triumeq's share loss is to one other brand.
Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare): Only two FDCs saw a net share gain because of barriers.
M2 EQUITYBITES-September 24, 2015-ViiV Healthcare reports 24-week data from virologically suppressed HIV-1 adults who switched from ART to once-daily, fixed-dose dolutegravir-based regimen, Triumeq
M2 PHARMA-September 24, 2015-ViiV Healthcare reports 24-week data from virologically suppressed HIV-1 adults who switched from ART to once-daily, fixed-dose dolutegravir-based regimen, Triumeq
Contract award notice: supply of the drug triumeq for the service of infectious diseases hospitalization of the university hospital ramn y cajal.
This growth will be driven primarily by the highly anticipated arrivals of novel integrase inhibitor- (INI-) and protease inhibitor- (PI-) based STRs, which include ViiV Healthcare's Triumeq (dolutegravir/abacavir/lamivudine), Gilead's Quad 2 (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]), and Gilead's and Janssen's darunavir/cobicistat/emtricitabine/TAF.
Arnuity Ellipta in respiratory, Triumeq in HIV and Tanzeum for type 2
M2 EQUITYBITES-August 26, 2014-ViiV Healthcare receives approval for Triumeq from US FDA
M2 PHARMA-August 26, 2014-ViiV Healthcare receives approval for Triumeq from US FDA
Contract award notice: Suministro de medicamentos: Triumeq (Dolutegravir + Abacavir + Lamivudina).
M2 EQUITYBITES-August 25, 2014-ViiV Healthcare wins US FDA's approval for single-pill regimen Triumeq tablets for HIV-1 infection